PATENT CLAIM ANALYSIS

Application Number: 15902491
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "183000"]

Abstract:
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Claim (Index 24):
The method of  claim 21 , wherein the second compound is gammaglobulin IV.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15046486', '15902498', '15895312', '15902486', '14437316']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8638109467698295
- 35 USC 102 Novelty (BERT): 0.571926161503062
- Combined Prediction Score: 0.8346224682431528
- Mean Citation Score: 569.6038599999998
- Max Citation Score: 582.98083
- Similarity Product: 346.33633130520934

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test